Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs

MicroRNAs (miRNAs) enable colonic epithelial cells to acquire malignant characteristics and metastatic capabilities. Recently, cancer relevant miRNAs deregulated during disease progression have also been identified in tumor-associated stroma. By combining laser-microdissection (LMD) with high-throughput screening and high-sensitivity quantitation techniques, miRNA expression in colorectal cancer (CRC) specimens and paired normal colonic tissue was independently characterized in stromal and epithelial tissue compartments. Notably, deregulation of the key oncogene miR-21 was identified exclusively as a stromal phenomenon and miR-106a, an epithelial phenomenon in the malignant state. MiRNAs identified in this study successfully distinguished CRC from normal tissue and metastatic from non-metastatic tumor specimens. Furthermore, in a separate cohort of 50 consecutive patients with CRC, stromal miR-21 and miR-556 and epithelial miR-106a expression predicted short disease free survival (DFS) and overall survival (OS) in stage II disease: miR-21 (DFS: HR = 2.68, p = 0.015; OS: HR = 2.47, p = 0.029); miR-556 (DFS: HR = 2.60, p = 0.018); miR-106a (DFS: HR = 2.91, p = 0.008; OS: HR = 2.25, p = 0.049); combined (All High vs. All Low. DFS: HR = 5.83, p = 0.002; OS: HR = 4.13, p = 0.007). These data support the notion that stromal as well as epithelial miRNAs play important roles during disease progression, and that mapping patterns of deregulated gene expression to the appropriate tumor strata may be a valuable aid to therapeutic decision making in CRC.

[1]  George A Calin,et al.  Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. , 2014, Cancer cell.

[2]  O. Lingjaerde,et al.  Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first‐line oxaliplatin‐based treatment , 2014, Molecular oncology.

[3]  F. Sánchez‐Madrid,et al.  Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs , 2013, Nature Communications.

[4]  G. Packham,et al.  miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. , 2013, Cancer research.

[5]  Yoshiyuki Yamamoto,et al.  Fecal miR-106a Is a Useful Marker for Colorectal Cancer Patients with False-Negative Results in Immunochemical Fecal Occult Blood Test , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[6]  B. Nielsen,et al.  Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression , 2013, Cell Death and Disease.

[7]  G. Packham,et al.  FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role , 2013, British Journal of Cancer.

[8]  Y. Toiyama,et al.  Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. , 2013, Journal of the National Cancer Institute.

[9]  D. Scadden,et al.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. , 2013, The Journal of clinical investigation.

[10]  P. Gibbs,et al.  Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. , 2013, Critical reviews in oncology/hematology.

[11]  Min Liu,et al.  MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. , 2012, Cancer letters.

[12]  S. Rai,et al.  Plasma MiR-21: A Potential Diagnostic Marker of Colorectal Cancer , 2012, Annals of surgery.

[13]  M. Zheng,et al.  Colorectal Cancer Migration and Invasion Initiated by microRNA-106a , 2012, PloS one.

[14]  Kazuo Ikeda,et al.  Induction of microRNA-214-5p in human and rodent liver fibrosis , 2012, Fibrogenesis & tissue repair.

[15]  Gerald Hoefler,et al.  miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. , 2012, Carcinogenesis.

[16]  Kenichi Sugihara,et al.  Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters , 2012, Clinical Cancer Research.

[17]  M. Fukushima,et al.  Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells , 2012, Journal of Gastroenterology.

[18]  Ara Darzi,et al.  Preparing for precision medicine. , 2012, The New England journal of medicine.

[19]  A. Eggermont,et al.  Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population‐based series , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[20]  Michael C. Ostrowski,et al.  Reprogramming of the Tumor Microenvironment by Stromal Pten-regulated miR-320 , 2011, Nature Cell Biology.

[21]  Yi Zheng,et al.  miR‐21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells , 2011, FEBS letters.

[22]  F. Su,et al.  Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells , 2011, Molecular Cancer.

[23]  Jun Yu,et al.  Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps , 2011, Gut.

[24]  A. Gaur,et al.  Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. , 2011, Neuro-oncology.

[25]  Timothy R Pal,et al.  Prognostic significance of miR-215 in colon cancer. , 2011, Clinical colorectal cancer.

[26]  M. Wei,et al.  Micro‐RNA‐21 regulates TGF‐β‐induced myofibroblast differentiation by targeting PDCD4 in tumor‐stroma interaction , 2011, International journal of cancer.

[27]  H. Nielsen,et al.  High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients , 2010, Clinical & Experimental Metastasis.

[28]  Jing Li,et al.  Secreted monocytic miR-150 enhances targeted endothelial cell migration. , 2010, Molecular cell.

[29]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[30]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[31]  C. Kang,et al.  Downregulation of miR-21 Enhances Chemotherapeutic Effect of Taxol in Breast Carcinoma Cells , 2010, Technology in cancer research & treatment.

[32]  Lei Han,et al.  MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol , 2010, BMC Cancer.

[33]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[34]  Marek Svoboda,et al.  MicroRNAs in colorectal cancer: translation of molecular biology into clinical application , 2009, Molecular Cancer.

[35]  A. Schetter,et al.  MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers , 2009, Proceedings of the National Academy of Sciences.

[36]  K. Ohuchida,et al.  MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance , 2009, Molecular Cancer Therapeutics.

[37]  R. Gregory,et al.  Many roads to maturity: microRNA biogenesis pathways and their regulation , 2009, Nature Cell Biology.

[38]  Xin Zhang,et al.  p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. , 2008, Cancer research.

[39]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[40]  C. Klein,et al.  The Metastasis Cascade , 2008, Science.

[41]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[42]  T. Wurdinger,et al.  MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators , 2008, Molecular and Cellular Biology.

[43]  E. Labourier,et al.  Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. , 2008, The Journal of molecular diagnostics : JMD.

[44]  H. Allgayer,et al.  MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer , 2008, Oncogene.

[45]  George A Calin,et al.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. , 2008, JAMA.

[46]  Kazuhiko Hayashi,et al.  Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. , 2007, RNA.

[47]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[48]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[49]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  C. Lepage,et al.  Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population , 2006, The British journal of surgery.

[51]  A. Shorthouse,et al.  Association of Coloproctology of Great Britain and Ireland: News , 1999 .

[52]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[53]  A. Benson,et al.  Adjuvant therapy in stage II colon cancer: current approaches. , 2005, The oncologist.

[54]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[55]  D. Sargent,et al.  Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[57]  陆星华,et al.  Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis , 2001 .

[58]  P. Simmonds,et al.  Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis , 2000, BMJ : British Medical Journal.

[59]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[60]  K. Okuno,et al.  Lymph node metastases detected in the mesorectum distal to carcinoma of the rectum by the clearing method: justification of total mesorectal excision. , 1997, Journal of the American College of Surgeons.

[61]  P. Quirke,et al.  Total mesorectal excision and local recurrence: A study of tumour spread in the mesorectum distal to rectal cancer , 1995, The British journal of surgery.

[62]  E. van Rooij,et al.  MicroRNA-214 antagonism protects against renal fibrosis. , 2014, Journal of the American Society of Nephrology : JASN.

[63]  Alberto Izzotti,et al.  MicroRNAs in cancer treatment and prognosis. , 2012, American journal of cancer research.

[64]  Jing Liu,et al.  MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN , 2012, Molecular and Cellular Biochemistry.

[65]  I. Fidler,et al.  Cancer metastasis. , 1991, British medical bulletin.